GlassScriptPhysician profile
Brian Ck Au
NPI 1346444940
$10,775.54
in general payments reported to CMS, 2019-2025
30 companies · $1,873 in 2025
The $1,873 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $764 · 2020: $1,277 · 2021: $1,488 · 2022: $1,688 · 2023: $1,743 · 2024: $1,942 · 2025: $1,873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,558.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,259.99 | 2019-2025 | Rocklatan, Clareon, Argos |
| Bausch & Lomb Americas INC. | $1,091.53 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Abbvie INC. | $1,001.51 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $884.81 | 2019-2021 | |
| Oyster Point Pharma, INC. | $674.86 | 2022-2025 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $540.03 | 2019-2023 | |
| Allergan, INC. | $482.58 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $343.71 | 2019-2025 | Cequa |
| Johnson & Johnson Surgical Vision, INC. | $328.47 | 2021-2024 | Tecnis Simplicity, Whitestar Signature |
| Ocular Therapeutix, INC. | $252.95 | 2019-2025 | Dextenza |
| Tarsus Pharmaceuticals, INC. | $252.92 | 2024-2025 | Xdemvy |
| Astellas Pharma US INC | $247.17 | 2024-2025 | Izervay |
| Amgen INC. | $231.34 | 2024-2025 | Tepezza |
| Harrow Eye, LLC | $207.87 | 2024-2025 | Vevye |
| Dompe US, INC. | $204.49 | 2021-2025 | Oxervate |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $200.94 | 2019-2021 | |
| New World Medical,INC. | $200.88 | 2025 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Carl Zeiss Meditec USA, INC. | $191.29 | 2023-2024 | Atlas 500, Humphrey Hfa |
| Biotissue Holdings INC. | $185.98 | 2019-2025 | |
| Sight Sciences, INC. | $177.62 | 2020-2025 | Omni Surgical System, Sion Surgical Instrument |
| Kala Pharmaceuticals, INC. | $150.43 | 2021-2022 | |
| Horizon Therapeutics Plc | $145.55 | 2022-2023 | Tepezza |
| Carl Zeiss Meditec, INC. | $104.66 | 2020 | |
| Eyevance Pharmaceuticals LLC | $93.96 | 2019-2020 | |
| Shire North American Group INC | $86.49 | 2019 | |
| Glaukos Corporation | $84.35 | 2020-2024 | Idose, Istent Trabecular Micro-Bypass System Model Is3 |
| Mallinckrodt Hospital Products INC. | $50.28 | 2020-2022 | |
| Thea Pharma INC. | $39.84 | 2024-2025 | Iyuzeh |
| Akorn Operating Company LLC | $36.38 | 2021 | |
| Merz North America, INC. | $22.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Au listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.